The next big question in cancer immunotherapy is what’s next in immune-oncology? Overcoming resistance to various combinatorial approaches, selecting the patients and developing translational hypothesis besides designing optimal preclinical models for immunological agents, different strategies to regulate the microbiome are some of the major challenges faced by cancer research experts in the US.
There have been remarkable advancements in cancer immunotherapy especially in the clinical development of immune checkpoint inhibitors, neoantigen-based immunotherapy and microbiome-derived immunotherapy in cancer. One of the most promising approach in terms of ACT (Adoptive Cell Transfer) is the CAR-T cell therapy which has recently received its second approval from the FDA.
Following the success of our UK Edition, MarketsandMarkets is proud to announce the Next Gen Immuno-Oncology Congress-US Edition to be held on 21st and 22nd June 2018 in Philadelphia, USA. The congress aims to bring academicians, researchers and scientists from research institutes pharmaceutical, bio-pharmaceutical and biotechnology companies to address the latest updates in development of CAR-T cell therapy, neoantigen-based and microbiome-derived immunotherapy and new paradigms in immune checkpoint inhibitors. This congress would also focus on various combination strategies, pre-clinical and translational immune-oncology developments, updates in cellular and viral therapies, vaccines development and personalized immunotherapy. Keynote presentations, Brainstorming Panel Discussions and Case studies will give the stakeholders an opportunity to discuss and understand the issues faced and come up with solutions.